<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Constantinescu, Cris S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Therapies for Cognitive Impairment and Neurological Protection</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses discussed cognitive impairment in relationship to multiple sclerosis (MS). Cognitive impairment is seen in &gt;65% of patients in clinical studies of MS [Fischer JS et al. Ann Neurol. 2000]. The impairment has been documented in all subtypes and stages of MS [Amato MP et al. Neurology. 2010; Amato MP et al. Neurology. 2008; Potagas C et al. J Neurol Sci. 2008; Amato MP et al. J Neurol. 2006; Fischer JS et al. Ann Neurol. 2000].</style></abstract><number><style face="normal" font="default" size="100%">29</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>